Crystal Rock Capital Management Purchases 4,265 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Crystal Rock Capital Management increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 90.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,005 shares of the company's stock after purchasing an additional 4,265 shares during the period. IDEXX Laboratories accounts for 2.7% of Crystal Rock Capital Management's holdings, making the stock its 14th biggest holding. Crystal Rock Capital Management's holdings in IDEXX Laboratories were worth $4,550,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of IDEXX Laboratories by 1.2% in the first quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company's stock valued at $4,576,476,000 after purchasing an additional 98,387 shares during the period. American Century Companies Inc. grew its holdings in IDEXX Laboratories by 46.0% during the second quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after purchasing an additional 177,226 shares during the last quarter. International Assets Investment Management LLC boosted its stake in shares of IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in IDEXX Laboratories by 13.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock worth $249,855,000 after purchasing an additional 59,519 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in shares of IDEXX Laboratories by 12.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company's stock valued at $190,283,000 after purchasing an additional 43,473 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IDXX shares. BTIG Research assumed coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a "buy" rating and a $580.00 target price on the stock. Piper Sandler reaffirmed a "neutral" rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research report on Thursday, October 10th. Barclays lowered their target price on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. decreased their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus target price of $552.38.

IDEXX Laboratories Price Performance

Shares of IDXX stock traded down $9.10 during midday trading on Tuesday, reaching $428.20. 437,781 shares of the company traded hands, compared to its average volume of 499,032. The firm's 50 day simple moving average is $471.95 and its two-hundred day simple moving average is $484.70. IDEXX Laboratories, Inc. has a 1-year low of $404.74 and a 1-year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The firm has a market cap of $35.06 billion, a PE ratio of 42.17, a price-to-earnings-growth ratio of 3.78 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same quarter last year, the business earned $2.53 EPS. IDEXX Laboratories's revenue for the quarter was up 6.6% on a year-over-year basis. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.